Lv1
20 积分 2026-03-29 加入
Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: A multicenter cohort study
5天前
已关闭
Safety and Effectiveness of Eculizumab in Patients With Refractory Ocular or Ocular‐Predominant Myasthenia Gravis: A Case Series
6天前
已完结
Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report
6天前
已完结
Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors
6天前
已完结
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
6天前
已完结
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
1个月前
已完结
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
1个月前
已完结
C5 gene influences the development of murine myasthenia gravis
1个月前
已完结
Italian recommendations for the diagnosis and treatment of myasthenia gravis
1个月前
已完结
Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients
1个月前
已完结
皖公网安备34019202002308
